Shanghai Fosun Pharmaceutical (Group) Co has a current ratio of 0.93. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Shanghai Fosun Pharmaceutical (Group) Co has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
STU:08HH's Current Ratio is ranked worse than 85.73% of 995
companies
in the Drug Manufacturers industry
Industry Median: 2
vs STU:08HH: 0.93
Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Shanghai Fosun Pharmaceutical (Group) Co Current Ratio Related Terms
Shanghai Fosun Pharmaceutical (Group) Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co Current Ratio Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co Current Ratio vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) has a Current Ratio of 0.93 as of Mar. 2026. This is near median its historical median of 1.01. Over the past decade, Shanghai Fosun Pharmaceutical (Group) Co's Current Ratio has ranged from 0.74 to 1.48. According to the industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #853 out of 995 companies in the Drug Manufacturers industry, placing it in the top 85.7%.
Is Shanghai Fosun Pharmaceutical (Group) Co's Current Ratio too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Current Ratio of 0.93 is near median its 10-year median of 1.01. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 1.48. The Drug Manufacturers industry median Current Ratio is 2.00. Shanghai Fosun Pharmaceutical (Group) Co's value of 0.93 is 53.5% below this industry median. Based on the distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #853 out of 995 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #853 out of 995 companies for Current Ratio. This places Shanghai Fosun Pharmaceutical (Group) Co in the lower half of its industry. The industry median Current Ratio is 2.00. Shanghai Fosun Pharmaceutical (Group) Co's value of 0.93 is 53.5% below this benchmark. Historically, Shanghai Fosun Pharmaceutical (Group) Co's own Current Ratio has ranged from 0.74 to 1.48 over the past decade. While the company's 10-year median is 1.01 vs. the industry median of 2.00, Shanghai Fosun Pharmaceutical (Group) Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fosun Pharmaceutical (Group) Co's current Current Ratio of 0.93 is 53.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fosun Pharmaceutical (Group) Co's current Current Ratio is 0.93, which is near median its own 10-year median of 1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.11, compared to a current price of €1.81 — trading 14.2% below its estimated fair value. The current Current Ratio is 0.93, which is near median its 10-year median of 1.01 and 53.5% below the Drug Manufacturers industry median of 2.00. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 69/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH), the current Current Ratio is 0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of €1.81 is trading 14.2% below its estimated GF Value™ of €2.11.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.
Key valuation signals for STU:08HH:
Current Ratio: 0.93 (near median its 10-year median of 1.01)
GF Value™: €2.11 vs. price of €1.81 (14.2% below fair value)
Industry Position: 53.5% below the Drug Manufacturers median (#853 of 995)
No single metric tells the full story. See the STU:08HH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
69GF Score
Get the complete analysis for STU:08HH
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:08HH has been successfully added to your 
